A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN) (G0102598)
Primary Objective
To demonstrate the superiority of iptacopan compared to placebo in reducing proteinuria at 6 months of treatment
Description
Assess efficacy and safety of iptacopan compared to placebo and standard of care in adults and adolescents (12-17) with IC-MPGN in native Kidneys
Details
Age
Child to Adult
Eligibility
Age 12-60 at screening, diagnosis of idiopathic IC-MPGN by biopsy within 12 months for adults and within 3 years for adolescents.UPCR >1.0g/g, estimated GFR >= 30 ml/min/1.73m2 at screening, and up to date on vaccines
Locations
Childrens Hospital Colorado
University of Colorado Hospital
Principal Investigator
Bradley Dixon
Study ID
Protocol Number: 23-0839
More information available at ClinicalTrials.gov: NCT05755386
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers